Last updated July 17, 2026
Key finding
Overall mean weight change was -11.1 kg (-11.7%) with semaglutide.
This study investigated the effects of semaglutide on weight loss in adults with metabolic dysfunction-associated steatotic liver disease. Semaglutide led to a significant weight reduction compared to placebo.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
High Risk
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study investigated the effects of semaglutide on weight loss in adults with metabolic dysfunction-associated steatotic liver disease. Semaglutide led to a significant weight reduction compared to placebo.
The findings highlight semaglutide's potential as an effective treatment for weight management in adults suffering from metabolic dysfunction-associated steatotic liver disease. Given the rising prevalence of obesity and related metabolic disorders, effective interventions like semaglutide could significantly improve patient outcomes and reduce the burden of associated health risks.
The study's population may not be representative of all adults with metabolic liver disease. The long-term effects of semaglutide on weight maintenance were not assessed. No significant correlations were found between weight change and baseline metabolic markers.
Published in
Publication details and source links for this paper.
Matthew JA, Takeshi O, Mads SP, Anne‐Sophie S, Mohamed T, Michael R. Weight Loss with Semaglutide in Adults with Metabolic Dysfunction-Associated Steatotic Liver Disease. Diabetes, Obesity & Metabolism. 2024;27(2):710-718. doi:10.1111/dom.16065
Participants on semaglutide lost an average of -11.1 kg (-11.7%).
Participants on placebo lost an average of -0.7 kg (-0.6%).
The estimated treatment difference was -10.4 kg (95% CI -11.9, -8.9).
Weight loss with semaglutide was -10.2 kg for those with type 2 diabetes.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Semaglutide and Correlation of weight change with HbA1c, Correlation of weight change with lipid levels, Fasting blood sugar (FBS), and 2 more.
This study contributes evidence to
Primary intervention
Semaglutide
Primary outcomes
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
4
Related topics
5
Evidence pairs
678
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Related evidence
Evidence relationship
Save evidence
Evidence relationship
Save evidence
Core evidence
The primary outcomes reported in this study.
Semaglutide → Correlation of weight change with HbA1c
Semaglutide → Correlation of weight change with HbA1c
Semaglutide → Correlation of weight change with lipid levels
Semaglutide → Correlation of weight change with lipid levels
Semaglutide → Fasting blood sugar (FBS)
Semaglutide → Fasting blood sugar (FBS)
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Body Weight, GLP-1 Receptor Agonists and Correlation of weight change with HbA1c.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring Body Weight
Measures Body Weight as a key outcome.
All studies on GLP-1 Receptor Agonists
Contributes to GLP-1 Receptor Agonists evidence base.
All studies measuring Correlation of weight change with HbA1c
Measures Correlation of weight change with HbA1c as a key outcome.
All studies measuring Fasting Glucose
Measures Fasting Glucose as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
2 results
1 results
2 results
2 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
GLP-1 Receptor Agonists appears to improve Body Weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Weight change
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is based on 30 supporting studies with consistent results and a positive effect signal.
Limitations
GLP-1 Receptor Agonists may improve Fasting Glucose.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
Fasting blood sugar (FBS)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 11 supporting studies with generally consistent results and a positive effect signal.
Limitations
GLP-1 Receptor Agonists may improve Insulin Resistance.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
Insulin resistance
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 6 supporting studies with generally consistent results and a positive effect signal.
Limitations
Current evidence does not show a clear benefit of Semaglutide for Correlation of weight change with HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Correlation of weight change with HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
